Realgar (As4S4), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway in vitro
Open Access
- 12 September 2022
- journal article
- research article
- Published by Impact Journals, LLC in Aging
- Vol. 14 (17), 7109-7125
- https://doi.org/10.18632/aging.204281
Abstract
Acute promyelocytic leukemia (APL) is a specific subtype of acute myelogenous leukemia (AML) characterized by the proliferation of abnormal promyelocytes. Realgar, a Chinese medicine containing arsenic, can be taken orally. Traditional Chinese medicine physicians have employed realgar to treat APL for over a thousand years. Therefore, realgar may be a promising candidate for the treatment of APL. Nevertheless, the underlying mechanism behind realgar therapy is largely unclear. The present study aimed to investigate the effect of realgar on cell death in the APL cell line (NB4) in vitro and to elucidate the underlying mechanism. In this study, after APL cells were treated with different concentrations of realgar, the cell survival rate, apoptotic assay, morphological changes, ATP levels and cell cycle arrest were assessed. The expression of Bcl-2, Bax, Cytochrome C (Cyt-C) and apoptosis-inducing factor (AIF) at the mRNA and protein levels were also measured by immunofluorescence, quantitative PCR (qPCR) and Western blotting. We found that realgar could significantly inhibit APL cell proliferation and cell death in a time- and dose-dependent manner. Realgar effectively decreased the ATP levels in APL cells. Realgar also induced APL cell cycle arrest at the S and G2/M phases. Following realgar treatment, the mRNA and protein levels of Bcl-2 were significantly downregulated, whereas the levels of Bax, Cyt-C, and AIF were significantly upregulated. In summary, realgar can induce APL cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway, suggesting that realgar may be an effective therapeutic for APL.Keywords
This publication has 54 references indexed in Scilit:
- Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemiaBlood, 2012
- Realgar-induced apoptosis and differentiation in all-trans retinoic acid (ATRA)-sensitive NB4 and ATRA-resistant MR2 cellsInternational Journal of Oncology, 2011
- Mitochondria in Apoptosis: Bcl-2 Family Members and Mitochondrial DynamicsDevelopmental Cell, 2011
- Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survivalBlood, 2009
- Mineral Arsenicals in Traditional Medicines: Orpiment, Realgar, and ArsenoliteThe Journal of pharmacology and experimental therapeutics, 2008
- Apoptosis: controlled demolition at the cellular levelNature Reviews Molecular Cell Biology, 2008
- Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcomeEuropean Journal of Haematology, 2006
- Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grindingEuropean Journal of Pharmaceutical Sciences, 2006
- Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular featuresLeukemia, 2006
- Molecular Analysis of Acute Promyelocytic Leukemia Breakpoint Cluster Region on Chromosome 17Science, 1990